| Modulators of pnpla3 expression |
2023-8-21 |
2023-9-07 |
|
| Compounds and methods for reducing pln expression |
2023-7-26 |
2023-9-01 |
|
| Modulators of pcsk9 expression |
2023-7-20 |
2023-9-01 |
|
| Compounds and methods for reducing LRRK2 expression |
2023-7-13 |
2023-9-27 |
|
| Compounds and methods for modulating huntingtin |
2023-7-03 |
2023-9-01 |
|
| Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
2023-6-16 |
2023-8-17 |
|
| Compositions and methods for modulating HBV and TTR expression |
2023-6-07 |
2023-8-16 |
|
| Composite antisense compounds and uses thereof |
2023-5-24 |
2023-8-22 |
|
| Regulation of apolipoprotein(a) expression |
2023-5-19 |
2023-8-22 |
|
| Regulators of EZH2 expression |
2023-5-02 |
2023-7-19 |
|
| Compounds and methods for modulating angiotensinogen expression |
2023-4-21 |
2023-7-04 |
|
| Rnai agents of modulating plp1 |
2023-3-23 |
2023-9-28 |
|
| Modulators of APOL1 expression |
2023-3-15 |
2023-5-30 |
|
| COMPOUNDS AND METHODS TO MODULATE SCN2A |
2023-3-03 |
2023-5-31 |
|
| Modulators of irf4 expression |
2023-3-02 |
2023-5-23 |
|
| Rnai agents of prion expression |
2023-2-27 |
2023-8-31 |
|
| Compounds and methods for modulating atn1 expression |
2023-2-24 |
2023-9-28 |
|
| Compounds and methods for modulating atn1 expression |
2023-2-24 |
2023-8-31 |
|
| Modulation of factor 11 expression |
2023-1-05 |
2023-8-24 |
|
| Compounds and methods for reducing glycogen synthase 1 |
2022-12-21 |
2023-9-28 |
|
| Compounds and methods for reducing pcdh19 expression |
2022-12-21 |
2023-9-21 |
|
| Compounds and methods for reducing glycogen synthase 1 |
2022-12-21 |
2023-6-29 |
|
| Compounds and methods for modulating glycogen synthase 1 |
2022-12-21 |
2023-6-29 |
|
| Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof |
2022-12-16 |
2023-9-07 |
|
| Compounds and methods for modulation of smn2 |
2022-12-15 |
2023-3-01 |
|
| Compositions for modulating ataxin 2 expression |
2022-12-09 |
2023-3-01 |
|
| Modulators of foxp3 expression |
2022-11-29 |
2023-6-29 |
|
| Compounds and methods for modulating plp1 |
2022-11-23 |
2023-1-01 |
|
| Compositions and Methods for Modulation of SMN2 Splicing in a Subject |
2022-11-22 |
2023-6-15 |
|
| Compounds and methods for modulating progranulin expression |
2022-11-18 |
2023-5-25 |
|
| Methods for treating hypercholesterolemia |
2022-11-15 |
2023-5-04 |
|
| Compounds and methods for reducing psd3 expression |
2022-10-31 |
2023-6-22 |
|
| Compounds and methods for reducing SNCA expression |
2022-10-26 |
2023-1-24 |
|
| Compounds and methods for modulating atxn1 |
2022-10-19 |
2022-12-01 |
|
| Compounds and methods for reducing tau expression |
2022-10-07 |
2023-4-20 |
|
| Compounds and methods for modulation of transcript processing |
2022-10-07 |
2022-12-20 |
|
| Conjugated oligonucleotides and uses thereof |
2022-9-29 |
2023-4-06 |
|
| Compounds and methods to modulate smn2 |
2022-9-23 |
2022-10-11 |
|
| Compounds and methods for reducing dnm1l or drp1 expression |
2022-9-16 |
2023-3-23 |
|
| Compounds and methods for reducing dmpk expression |
2022-8-31 |
2023-4-13 |
|
| Compounds and methods for reducing dmpk expression |
2022-8-31 |
2023-3-09 |
|
| Compounds and methods for modulating scn1a expression |
2022-8-26 |
2023-4-13 |
|
| Oligomeric compounds comprising backbone constrained macrocycles |
2022-8-25 |
2023-3-30 |
|
| Compositions and methods for modulating PKK expression |
2022-8-17 |
2022-11-09 |
|
| Linkage modified oligomeric compounds and uses thereof |
2022-8-17 |
2023-2-23 |
|
| Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression |
2022-7-21 |
2023-6-08 |
|
| Modulation of Huntingtin Expression |
2022-7-18 |
2023-1-26 |
|
| Gene therapy and targeted delivery of conjugated compounds |
2022-7-13 |
2023-6-29 |
|
| Modulation of nox4 expression |
2022-6-30 |
2023-1-05 |
|
| Method for synthesis of linkage modified oligomeric compounds |
2022-6-29 |
2023-1-05 |
|
| Compounds and Methods for Reducing ATXN3 Expression |
2022-6-29 |
2023-7-27 |
|
| Modified crispr rna and modified single crispr rna and uses thereof |
2022-6-27 |
2023-5-25 |
|
| Compounds and methods for reducing ifnar1 expression |
2022-6-17 |
2022-12-22 |
|
| Compounds and methods for reducing IFNAR1 expression |
2022-6-17 |
2023-9-12 |
2023-9-12 |
| Compounds and methods for modulating angiotensinogen expression |
2022-6-02 |
2022-9-22 |
|
| Compounds for reducing ptbp1 expression |
2022-5-20 |
2022-12-29 |
|
| Compounds for modulating unc13a expression |
2022-5-20 |
2022-11-24 |
|
| Modulators of growth hormone receptor |
2022-5-19 |
2023-5-11 |
|
| Modulation of coasy expression |
2022-5-19 |
2022-11-24 |
|
| Methods and compositions for modulating alpha-1-antitrypsin expression |
2022-5-09 |
2023-7-06 |
|
| Methods for reducing agt expression |
2022-4-29 |
2022-11-03 |
|
| Compositions for Modulating C9ORF72 Expression |
2022-4-15 |
2023-4-13 |
|
| Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof |
2022-4-06 |
2023-4-20 |
|
| Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
2022-4-05 |
2022-7-12 |
|
| Compounds and Methods for Reducing LRRK2 Expression |
2022-4-04 |
2023-4-13 |
|
| Modulators of diacylglycerol acyltransferase 2 (dgat2) |
2022-4-04 |
2022-7-20 |
|
| Selective Antisense Compounds and Uses Thereof |
2022-4-04 |
2023-4-13 |
|
| Modified Compounds and Uses Thereof |
2022-3-17 |
2023-3-02 |
|
| Compositions and methods for modulating growth hormone receptor expression |
2022-3-07 |
2023-4-20 |
|
| Compound and method for modulating tmprss6 expression |
2022-3-04 |
2022-7-12 |
|
| Purification methods for oligomeric compounds |
2022-3-02 |
2022-9-09 |
|
| Compounds and methods for modulation of dystrophia myotonica-protein kinase ( … |
2022-2-28 |
2022-5-13 |
|
| Modulation of marc1 expression |
2022-2-25 |
2022-9-01 |
|
| Compositions and methods for modulating ataxin 3 expression |
2022-2-23 |
2023-2-09 |
|
| Compounds and methods for reducing nlrp3 expression |
2022-2-17 |
2022-8-25 |
|
| Linkage modified oligomeric compounds and uses thereof |
2022-2-15 |
2023-4-18 |
2023-4-18 |
| Linkage modified oligomeric compounds and uses thereof |
2022-2-11 |
2022-8-18 |
|
| Modulators of malat1 expression |
2022-2-08 |
2022-8-04 |
|
| Compounds and methods for modulating c90rf72 |
2022-2-04 |
2023-1-19 |
|
| Modulators of complement factor b |
2022-1-28 |
2022-4-12 |
|
| Selective antisense compounds and uses thereof |
2022-1-27 |
2023-1-05 |
|
| Compounds and methods for reducing dux4 expression |
2022-1-21 |
2022-7-28 |
|
| Selective Reduction of Allelic Variants |
2022-1-18 |
2022-12-22 |
|
| Compounds and Methods for Modulating UBE3A-ATS |
2022-1-14 |
2022-12-29 |
|
| Modulation of gys1 expression |
2021-12-23 |
2022-4-14 |
|
| Compounds and methods for modulating factor xii |
2021-12-17 |
2022-7-28 |
|
| Antisense compounds and uses thereof |
2021-12-16 |
2022-11-24 |
|
| Compounds and methods for modulating expression of angiotensinogen |
2021-11-18 |
2023-8-18 |
|
| Modulators of yap1 expression |
2021-11-16 |
2022-10-06 |
|
| BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) |
2021-11-12 |
2022-6-23 |
|
| Compositions and methods for enhanced intestinal absorption of conjugated … |
2021-11-09 |
2022-6-16 |
|
| Modulators of irf5 expression |
2021-11-03 |
2022-2-17 |
|
| 2'-methoxy substituted oligomeric compounds and compositions for use in gene … |
2021-11-03 |
2022-9-15 |
|
| Compounds and methods for increased antisense activity |
2021-10-29 |
2022-5-05 |
|
| Compounds and methods for reducing spdef expression |
2021-10-22 |
2022-9-15 |
|
| Compounds and methods for reducing the expression of fxi - divisional … |
2021-10-15 |
2022-7-22 |
|
| Compounds and methods to reduce kcnt1 expression |
2021-10-06 |
2021-10-20 |
|
| Methods and compositions for inhibiting pmp22 expression |
2021-10-04 |
2022-8-11 |
|
| Compounds for modulating chmp7 |
2021-10-01 |
2023-8-09 |
|
| Compositions and methods for modulating angiopoietin-like 3 expression |
2021-9-29 |
2021-10-28 |
|